Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc.

Biomea Fusion is a clinical-stage biopharmaceutical company focused on discovering and developing oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers.  Biomea Fusion's lead investigational compound, BMF-219, is a covalent menin inhibitor.  The company also develops BMF-500, a covalent FLT3 inhibitor.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.02 -	5.76 25,713.81%	8.53 48.06%	3.91 54.12%	5.19 32.51%
company equity multiplier	-12.62 -	12.10 195.86%	1.04 91.41%	1.19 14.69%	1.18 0.84%
days of inventory outstanding
days of payables outstanding					595.24 -
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1.00 -	1.00 0.31%	1.00 0.18%	0.98 1.92%	0.93 4.99%
effective tax rate	-0.00 -	0.00 122.50%	0.01 1,390.02%	0.02 162.87%
enterprise value multiple	-152.13 -	-22.67 85.10%	-0.12 99.49%	-1.62 1,292.47%	-2.70 66.19%
fixed asset turnover
free cash flow per share	-0.12 -	-0.42 252.62%	-1.62 284.22%	-2.17 33.94%	-2.93 35.22%
gross profit margin
interest coverage				46.31 -
inventory turnover
long term debt to capitalization			0.01 -	0.02 19.86%	0.04 192.34%
net income per ebt	1.00 -	1.00 0.31%	0.99 0.78%	0.98 1.38%	1 2.26%
net profit margin
operating cash flow per share	-0.12 -	-0.42 248.63%	-1.49 256.70%	-2.13 43.56%	-2.83 32.81%
operating profit margin
payables turnover					0.61 -
pretax profit margin
price fair value	-8.67K -	35.22 100.41%	0.99 97.18%	2.27 128.67%	2.93 28.71%
receivables turnover
return on assets	-4.53 -	-0.09 98.12%	-0.22 160.81%	-0.62 178.82%	-0.59 5.23%
return on capital employed	56.90 -	-0.09 100.15%	-0.23 163.11%	-0.76 229.78%	-0.71 6.13%
return on equity	57.19 -	-1.03 101.80%	-0.23 77.60%	-0.74 219.79%	-0.69 6.02%
total debt to capitalization		0.05 -	0.02 67.12%	0.02 31.40%	0.06 178.15%

COM:BIOMEAFUSION

Biomea Fusion

Last Close

6.38

22/11 21:00

Market Cap

170.74M

Beta: -

Volume Today

490.54K

Avg: -

Preview